GlassScriptPhysician profile
Amanda Peebles Hall
NPI 1548771678
$14,556.94
in general payments reported to CMS, 2019-2025
58 companies · $3,800 in 2025
The $3,800 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,239 · 2022: $1,018 · 2023: $2,886 · 2024: $4,614 · 2025: $3,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,115.87 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,717.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,149.88 | 2021-2025 | |
| Sk Life Science, INC. | $923.79 | 2021-2025 | Xcopri |
| Pfizer INC. | $837.93 | 2023-2025 | |
| Lilly USA, LLC | $637.75 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $607.67 | 2021-2025 | |
| Biogen, INC. | $573.92 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Ucb, INC. | $521.71 | 2021-2025 | Nayzilam, Briviact, Rystiggo |
| Emd Serono, INC. | $502.40 | 2021-2025 | Mavenclad |
| Lundbeck LLC | $479.39 | 2021-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $447.33 | 2021-2025 | Valtoco |
| Ani Pharmaceuticals, INC. | $432.24 | 2023-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $422.98 | 2023-2025 | Hyqvia, Trintellix |
| Axsome Therapeutics, INC. | $312.99 | 2024-2025 | Sunosi, Symbravo |
| Argenx US, INC. | $277.81 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $256.06 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Impel Pharmaceuticals INC. | $239.16 | 2022-2023 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $229.39 | 2021-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $215.54 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $206.07 | 2023-2025 | Fycompa |
| Amneal Pharmaceuticals LLC | $202.13 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Genentech USA, INC. | $199.53 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Otsuka America Pharmaceutical, INC. | $184.82 | 2023-2024 | Rexulti, Nuedexta |
| Amgen INC. | $173.12 | 2021-2025 | Uplizna |
| Scilex Pharmaceuticals INC. | $152.16 | 2023-2024 | Ztlido |
| Janssen Pharmaceuticals, INC | $118.93 | 2021 | |
| Genzyme Corporation | $111.73 | 2021-2025 | |
| Harmony Biosciences LLC | $109.09 | 2023-2025 | Wakix |
| Idorsia Pharmaceuticals US INC | $92.52 | 2022-2024 | Quviviq |
| Tg Therapeutics, INC. | $92.27 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $81.65 | 2024 | Ultomiris |
| Corium, LLC | $80.69 | 2022-2023 | Adlarity |
| Grifols USA, LLC | $78.54 | 2021-2023 | Gamunex-C |
| Octapharma USA, INC. | $61.65 | 2023-2024 | Panzyga |
| Tanabe Pharma America, INC. | $60.00 | 2024-2025 | Radicava |
| Upsher-Smith Laboratories LLC | $55.90 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $54.19 | 2021 | |
| Celgene Corporation | $53.84 | 2022-2023 | Zeposia |
| Azurity Pharmaceuticals, INC. | $52.60 | 2023-2024 | Horizant, Horizant |
| Avanir Pharmaceuticals, INC. | $51.90 | 2021 | |
| Arbor Pharmaceuticals, INC. | $50.65 | 2021 | |
| Kyowa Kirin, INC. | $45.40 | 2021 | |
| Almatica Pharma LLC | $44.24 | 2021 | |
| Globus Medical, INC. | $41.95 | 2025 | Senza |
| Inspire Medical Systems, INC. | $38.98 | 2023-2024 | Inspire |
| Merck Sharp & Dohme LLC | $29.81 | 2021 | |
| Organogenesis INC. | $28.75 | 2023 | Puraply |
| Avion Pharmaceuticals | $25.79 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.06 | 2022 | |
| Allergan, INC. | $23.42 | 2021 | |
| Merz Pharmaceuticals, LLC | $22.43 | 2025 | Xeomin, Inbrija, Ampyra |
| Medtronic, INC. | $20.90 | 2025 | Intellis Adaptivestim |
| Csl Behring | $20.17 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $19.79 | 2023 | Iovera, Exparel, Zilretta |
| Impel Pharmaceuticals LLC | $18.17 | 2025 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $16.00 | 2022 | |
| Mdd US Operations, LLC | $13.72 | 2024 | Gocovri |
| Acadia Pharmaceuticals INC | $13.22 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.